A
About
Relay Therapeutics is a clinical-stage drug discovery company headquartered in Cambridge, MA, that puts protein motion at the center of its research paradigm. Traditional drug discovery relies on static snapshots of protein structures—akin to viewing black-and-white photographs. Relay's Dynamo® Platform transforms this approach by generating high-definition, dynamic models of how proteins move and change shape over time, enabling scientists to identify new therapeutic opportunities that were previously invisible or considered undruggable. The Dynamo® Platform tightly integrates leading-edge experimental biology with advanced computational methods including AI and machine learning. This integration allows Relay's interdisciplinary team to model complex protein conformations, predict binding sites, and design small-molecule drugs with unprecedented precision. The platform bridges molecular dynamics simulations, structural biology, medicinal chemistry, and data science into a seamless, collaborative workflow. Relay's pipeline is focused on precision oncology and genetic disease, advancing a portfolio of promising therapeutic candidates into clinical trials. The company is committed to bringing life-changing medicines to patients who cannot wait, operating with a culture that is relentless, fearless, and deeply human-centered. Relay Therapeutics is best suited for enterprise-level pharmaceutical research partnerships, institutional investors, and academic collaborators seeking to advance the frontiers of AI-driven drug discovery.
Key Features
- Dynamo® Platform: A proprietary integration of experimental and computational tools that models protein motion in high resolution to identify and drug previously intractable targets.
- Motion-Based Drug Design: Goes beyond static protein structures to simulate dynamic conformational changes, revealing new binding sites and drug opportunities invisible to traditional methods.
- AI & Computational Integration: Combines machine learning, molecular dynamics simulations, structural biology, and medicinal chemistry in a unified, data-driven research workflow.
- Precision Oncology & Genetic Disease Pipeline: Advancing a portfolio of clinical-stage therapeutic candidates targeting cancers and genetic disorders with high unmet medical need.
- Interdisciplinary Collaboration: World-class team that integrates biology, chemistry, physics, and data science to accelerate drug discovery from target identification to clinical trials.
Use Cases
- Identifying and designing drugs for previously undruggable protein targets in cancer and genetic diseases.
- Applying AI and molecular dynamics simulations to model protein conformational changes for drug binding site discovery.
- Building an integrated drug discovery pipeline that bridges computational predictions with experimental validation.
- Advancing precision oncology therapeutics from early research through clinical-stage development.
- Partnering with institutional investors and pharmaceutical organizations to co-develop next-generation medicines.
Pros
- Unlocks Undruggable Targets: The motion-centric approach reveals therapeutic opportunities that static-structure methods consistently miss, dramatically expanding the druggable proteome.
- Integrated Experimental & Computational Approach: Seamlessly combines wet-lab data with AI-driven modeling, reducing the gap between computational predictions and real-world biological outcomes.
- Focused Clinical Pipeline: Relay maintains a disciplined focus on precision oncology and genetic disease, concentrating resources on areas with the greatest patient impact.
Cons
- Not a Self-Serve Platform: The Dynamo® Platform is an internal research infrastructure, not available as a standalone SaaS product for external users or smaller organizations.
- Limited Public Accessibility: Engagement with Relay's technology is largely restricted to clinical trial participants, institutional investors, and formal research partnerships.
- Enterprise-Only Scale: The complexity and cost of this type of drug discovery infrastructure makes it inaccessible to individual researchers or early-stage startups without significant funding.
Frequently Asked Questions
What is the Dynamo® Platform?
The Dynamo® Platform is Relay Therapeutics' proprietary drug discovery engine that integrates experimental biology and advanced computational methods—including AI and molecular dynamics—to model protein motion and identify new drug targets.
What diseases does Relay Therapeutics focus on?
Relay Therapeutics focuses primarily on precision oncology and genetic diseases, advancing a pipeline of clinical-stage therapeutic candidates in these areas.
How does motion-based drug design differ from traditional approaches?
Traditional drug discovery uses static protein structures, like black-and-white photos. Relay's approach models protein motion dynamically, like HD movies, revealing binding sites and drug opportunities that static methods cannot detect.
Can external researchers or companies access the Dynamo® Platform?
The Dynamo® Platform is an internal research system. External engagement with Relay Therapeutics typically occurs through formal partnerships, licensing, or investment relationships rather than direct platform access.
How can patients get involved with Relay Therapeutics?
Patients can visit the Relay Therapeutics website to explore current clinical trials and determine whether they may be eligible to participate in ongoing studies.
